Tesamorelin is a stabilized growth-hormone-releasing-hormone (GHRH) analog. It signals your own pituitary to release a natural pulse of growth hormone, rather than injecting GH directly. It is the only peptide in its class with FDA approval (for HIV-associated lipodystrophy), studied across multiple Phase III trials.
What sets it apart is where the fat loss happens: tesamorelin drives lipolysis specifically in visceral adipose tissue, the deep belly fat that wraps around your organs and drives metabolic disease, while sparing subcutaneous fat and lean muscle. In trials that meant roughly a 15% reduction in visceral fat over 26 weeks, alongside improved triglyceride levels.
PeRx ships Tesamorelin fully reconstituted from an FDA-registered 503A pharmacy. No mixing. Insulin syringes and a step-by-step guide arrive in the box. It is a single daily subcutaneous injection on a provider-determined schedule.